Table 6.

Endogenous 25-OHD levels and breast cancer risk

StudyStudy DesignNo. cases/controlsComparison*OR (95% CI)
Lowe et al., 2005 (19)Hospital-based case-control179/17925-OHD (ng/mL) <20 vs >605.83 (2.31-14.7)
Abbas et al., 2008 (21)Population-based case-control1,394/1,36525-OHD (ng/mL) ≥30 vs <120.31 (0.24-0.42)
Crew et al.Population-based case-control1,026/1,07525-OHD (ng/mL) ≥40 vs <200.56 (0.41-0.78)
Bertone-Johnson et al., 2005 (22)Nested case-control701/72425-OHD (ng/mL) ≥40 vs ≤200.73 (0.49-1.07)
Freedman et al., 2008 (23)Nested case-control1,005/1,00525-OHD (ng/mL) ≥33.7 vs <18.31.04 (0.75-1.45)
  • *For circulating concentration of 25-OHD, 1 ng/mL = 2.5 nmol/L.

  • For this study, breast cancer risk was analyzed by quintiles of plasma 25-OHD. Quintile cut points differed in the three batches of plasma 25-OHD measurements.